Citations

Clear

3942 citation(s) found for "To, Van".

Preclinical Aortic Atherosclerosis in Adolescents With Chronic Disease
Ververs, Francesca A. , Eikendal, Anouk L. M. , Kofink, Daniel , Nuboer, Roos , Hovenkamp, Gijs T., Kemps, Jitske J.A., Coenen, Iris C.J., Daems, Joëlle J. N., Claus, Laura R. , Ju, Yillie, Wulffraat, Nico , Monaco, Claudia , Grotenhuis, Heynric B. , Schipper, Henk S. , Claus, Laura R , Wulffraat, Nico M , Monaco, Claudia , Leiner, Tim , Schipper, Henk S , Westenberg, Jos J.M. , Daems, Joëlle J N , Ent, Cornelis Korstiaan van der , Boes, Marianne L. , Leiner, Tim

Mayo Clinic

Journal of the American Heart Association | July 13, 2022 | Volume: 11 | Issue: 14 | Pages: No page available

10.1161/jaha.122.024675 | PMID 35861840 Get It

Background Adolescents with chronic disease are often exposed to inflammatory, metabolic, and hemodynamic risk factors for early atherosclerosis. Since postmortem studies have shown that atherogenesis starts in the aorta, the CDACD (Cardiovascular Disease in Adolescents with Chronic Disease) study investigated preclinical aortic atherosclerosis in these adolescents. Methods and Results The cross‐sectional CDACD study enrolled 114 adolescents 12 to 18 years old with chronic disorders including juvenile idiopathic arthritis, cystic fibrosis, obesity, corrected coarctation of the aorta, and healthy controls with a corrected atrial septal defect. Cardiovascular magnetic resonance was used to assess aortic pulse wave velocity and aortic wall thickness, as established aortic measures of preclinical atherosclerosis. Cardiovascular magnetic resonance showed a higher aortic pulse wave velocity, which reflects aortic stiffness, and higher aortic wall thickness in all adolescent chronic disease groups, compared with controls ( P <0.05). Age (β=0.253), heart rate (β=0.236), systolic blood pressure (β=−0.264), and diastolic blood pressure (β=0.365) were identified as significant predictors for aortic pulse wave velocity, using multivariable linear regression analysis. Aortic wall thickness was predicted by body mass index (β=0.248) and fasting glucose (β=0.242), next to aortic lumen area (β=0.340). Carotid intima‐media thickness was assessed using ultrasonography, and was only higher in adolescents with coarctation of the aorta, compared with controls ( P <0.001). Conclusions Adolescents with chronic disease showed enhanced aortic stiffness and wall thickness compared with controls. The enhanced aortic pulse wave velocity and aortic wall thickness in adolescents with chronic disease could indicate accelerated atherogenesis. Our findings underscore the importance of the aorta for assessment of early atherosclerosis, and the need for tailored cardiovascular follow‐up of children with chronic disease.
Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy–Associated Putative Pathogenic Gene Variants in UK Biobank Participants
Shah, Ravi A. , Asatryan, Babken , Dabbagh, Ghaith Sharaf , Aung, Nay , Khanji, Mohammed Y , Lopes, Luís R. , Holmes, Anthony , Muser, Daniele , Landstrom, Andrew P. , Semsarian, Christopher , Owens, Anjali , Petersen, Steffen E. , Chahal, C. Anwar A. , Investigators, on behalf of the Genotype-First Approach, Sharaf Dabbagh, Ghaith , Muser, Daniele , Landstrom, Andrew P , Lee, Aaron Mark , Arora, Pankaj , Semsarian, Christopher , Somers, Virend K. , Owens, Anjali T , Munroe, Patricia B , Petersen, Steffen E , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Asatryan, Babken , Aung, Nay , Shah, Ravi A , Lopes, Luis Rocha , Duijvenboden, Stefan van , Arora, Pankaj , Somers, Virend K. , Munroe, Patricia B. , Investigators, on behalf of the Genotype-First Approach

Mayo Clinic

Circulation | July 11, 2022 | Volume: 146 | Issue: 2 | Pages: 110-124

10.1161/circulationaha.121.058143 | PMID 35708014 Get It

Background: There is a paucity of data regarding the phenotype of dilated cardiomyopathy (DCM) gene variants in the general population. We aimed to determine the frequency and penetrance of DCM-associated putative pathogenic gene variants in a general adult population, with a focus on the expression of clinical and subclinical phenotype, including structural, functional, and arrhythmic disease features. Methods: UK Biobank participants who had undergone whole exome sequencing, ECG, and cardiovascular magnetic resonance imaging were selected for study. Three variant-calling strategies (1 primary and 2 secondary) were used to identify participants with putative pathogenic variants in 44 DCM genes. The observed phenotype was graded DCM (clinical or cardiovascular magnetic resonance diagnosis); early DCM features, including arrhythmia or conduction disease, isolated ventricular dilation, and hypokinetic nondilated cardiomyopathy; or phenotype-negative. Results: Among 18 665 individuals included in the study, 1463 (7.8%) possessed ≥1 putative pathogenic variant in 44 DCM genes by the main variant calling strategy. A clinical diagnosis of DCM was present in 0.34% and early DCM features in 5.7% of individuals with putative pathogenic variants. ECG and cardiovascular magnetic resonance analysis revealed evidence of subclinical DCM in an additional 1.6% and early DCM features in an additional 15.9% of individuals with putative pathogenic variants. Arrhythmias or conduction disease (15.2%) were the most common early DCM features, followed by hypokinetic nondilated cardiomyopathy (4%). The combined clinical/subclinical penetrance was ≤30% with all 3 variant filtering strategies. Clinical DCM was slightly more prevalent among participants with putative pathogenic variants in definitive/strong evidence genes as compared with those with variants in moderate/limited evidence genes. Conclusions: In the UK Biobank, ≈1 of 6 of adults with putative pathogenic variants in DCM genes exhibited early DCM features potentially associated with DCM genotype, most commonly manifesting with arrhythmias in the absence of substantial ventricular dilation or dysfunction.
Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection
Karp, Emily E. , Gompel, Jamie J. Van , Van Gompel, Jamie J , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Reports | July 11, 2022 | Volume: 83 | Issue: 03 | Pages: e80-e82

10.1055/s-0042-1753519 | PMID 35832684 Get It

AbstractEsthesioneuroblastoma is a rare malignancy originating from the olfactory epithelium. Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.
The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited
Domenighetti, Cloé , Douillard, Venceslas , Sreelatha, Ashwin Ashok Kumar , Schulte, Claudia , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Gagliardi, Monica , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Guedes, Leonor Correia , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri, Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Vince, Nicolas , Elbaz, Alexis , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel , Bobbili, Dheeraj Reddy , Singleton, Andrew , Gourraud, Pierre‐Antoine , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Krainc, Dimitri , Farrer, Matthew J.

Mayo Clinic

Movement Disorders | July 10, 2022 | Volume: 37 | Issue: 9 | Pages: 1929-1937

10.1002/mds.29133 | PMID 35810454 Get It

AbstractBackgroundTwo studies that examined the interaction between HLA‐DRB1 and smoking in Parkinson's disease (PD) yielded findings in opposite directions.ObjectiveTo perform a large‐scale independent replication of the HLA‐DRB1 × smoking interaction.MethodsWe genotyped 182 single nucleotide polymorphism (SNPs) associated with smoking initiation in 12 424 cases and 9480 controls to perform a Mendelian randomization (MR) analysis in strata defined by HLA‐DRB1.ResultsAt the amino acid level, a valine at position 11 (V11) in HLA‐DRB1 displayed the strongest association with PD. MR showed an inverse association between genetically predicted smoking initiation and PD only in absence of V11 (odds ratio, 0.74, 95% confidence interval, 0.59–0.93, PInteraction = 0.028). In silico predictions of the influence of V11 and smoking‐induced modifications of α‐synuclein on binding affinity showed findings consistent with this interaction pattern.ConclusionsDespite being one of the most robust findings in PD research, the mechanisms underlying the inverse association between smoking and PD remain unknown. Our findings may help better understand this association. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry
Fagundes, Antônio , Berg, David D. , Park, Jeong‐Gun , Baird-Zars, Vivian M., Newby, L. Kristin , Barsness, Gregory W. , Miller, P. Elliott , Diepen, Sean van , Katz, Jason N. , Phreaner, Nicholas , Menon, Venu , Daniels, Lori B. , Bohula, Erin A. , Investigators, for the CCCTN, van Diepen, Sean , Roswell, Robert O , Menon, Venu , Daniels, Lori B , Morrow, David A , Bohula, Erin A , Newby, L Kristin , Berg, David , Roswell, Robert O. , Morrow, David A. , Investigators, for the CCCTN

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | July 5, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.121.008652 | PMID 35862019 Get It

Background: With the improvement in outcomes for acute coronary syndrome (ACS), the practice of routine admission to cardiac intensive care units (CICUs) is evolving. We aimed to describe the epidemiology of patients with ACS admitted to contemporary CICUs. Methods: Using the CCCTN (Critical Care Cardiology Trials Network) Registry for consecutive medical CICU admissions across 26 advanced CICUs in North America between 2017 and 2020, we identified patients with a primary diagnosis of ACS at CICU admission and compared patient characteristics, resource utilization, and outcomes to patients admitted with a non-ACS diagnosis and across sub-populations of patients with ACS, including by indication for CICU admission. Results: Of 10 118 CICU admissions, 29.4% (n=2978) were for a primary diagnosis of ACS, with significant interhospital variability (range, 13.4%–56.6%). Compared with patients admitted with a diagnosis other than ACS, patients with ACS had fewer comorbidities, lower acute severity of illness with less utilization of advanced CICU therapies (41.3% versus 66.1%, P <0.0001), and lower CICU mortality (5.4% versus 9.9%, P <0.0001). Monitoring alone, without another CICU indication at the time of admission, was the most frequent admission indication in patients with ACS (53.8%); less common indications in patients with ACS included respiratory insufficiency, shock, or the need for vasoactive therapy. Of patients with ACS admitted for monitoring alone, 94.8% did not subsequently require advanced intensive care unit therapies and had a low CICU length of stay (1.5 days [0.9–2.4] versus 2.6 [1.4–5.1], P <0.0001) and CICU mortality (0.6% versus 11.0%, P <0.0001), compared with patients with ACS with an admission indication beyond monitoring. Conclusions: In a registry of tertiary care CICUs, ACS represent ≈1/3 of all admissions with significant variability across hospitals. More than half of the ACS admissions to the CICU were for routine monitoring alone, with a low rate of complications and mortality. This observation highlights an opportunity for prospective studies to refine triage strategies for lower risk patients with ACS.
Exercise Testing in Heart Failure with Preserved Ejection Fraction: An Appraisal Through Diagnosis, Pathophysiology and Therapy – A Clinical Consensus Statement of the Heart Failure Association and European Association of Preventive Cardiology of the Europ
Wilhelm, Matthias , Craenenbroeck, Emeline M. Van , Boer, Rudolf A. de , Lund, Lars H. , Mancini, Donna , Filippatos, Gerasimos , Borlaug, Barry, de Boer, Rudolf A , Wilhelm, Matthias , Guazzi, Marco , Halle, Martin , Kemps, Hareld , Coats, Andrew J.S. , Borlaug, Barry A. , Pieske, Burkert

Mayo Clinic

European Journal of Heart Failure | July 1, 2022 | Volume: 24 | Issue: 8 | Pages: 1327-1345

10.1002/ejhf.2601 | PMID 35775383 Get It

Abstract Patients with heart failure with preserved ejection fraction (HFpEF) universally complain of exercise intolerance and dyspnoea as key clinical correlates. Cardiac as well as extracardiac components play a role for the limited exercise capacity, including an impaired cardiac and peripheral vascular reserve, a limitation in mechanical ventilation and/or gas exchange with reduced pulmonary vascular reserve, skeletal muscle dysfunction and iron deficiency/anaemia. Although most of these components can be differentiated and quantified through gas exchange analysis by cardiopulmonary exercise testing (CPET), the information provided by objective measures of exercise performance has not been systematically considered in the recent algorithms/scores for HFpEF diagnosis, by neither European nor US groups. The current clinical consensus statement by the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC) aims at outlining the role of exercise testing and its pathophysiological, clinical and prognostic insights, addressing the implications of a thorough functional evaluation from the diagnostic algorithm to the pathophysiology and treatment perspectives of HFpEF. Along with these goals, we provide a specific analysis of the evidence that CPET is the standard for assessing, quantifying, and differentiating the origin of dyspnoea and exercise impairment and even more so when combined with echocardiography and/or invasive haemodynamic evaluation. This will lead to improved quality of diagnosis when applying the proposed scores and may also help to implement the progressive characterization of the specific HFpEF phenotypes, a critical step toward the delivery of phenotype-specific treatments.
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra, Aaron , Gergoudis, Stephanie, Morales, George , Spyrou, Nikolaos , Shah, Jay , Kowalyk, Steven, Ayuk, Francis , Baez, Janna , Chanswangphuwana, Chantiya , Chen, Yi‐Bin , Choe, Hannah , DeFilipp, Zachariah , Gandhi, Isha , Holler, Ernst , Kapoor, Urvi , Kitko, Carrie L. , Lin, Jung-Yi, Pawarode, Attaphol , Rösler, Wolf, Schechter, Tal , Hyfte, Grace Van , Weber, Daniela , Wölfl, Matthias , Young, Rachel , Özbek, Umut , Ferrara, James L.M. , Hexner, Elizabeth , Lin, Jung-Yi , Merli, Pietro , Pulsipher, Michael A. , Qayed, Muna , Levine, John E , Spyrou, Nikolaos , Hexner, Elizabeth O. , Hogan, William J. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Levine, John E.

Mayo Clinic

Blood Advances | June 23, 2022 | Volume: 6 | Issue: 12 | Pages: 3707-3715

10.1182/bloodadvances.2022007296 | PMID 35443021 Get It

Abstract We used a rigorous PRoBE (prospective-specimen collection, retrospective-blinded-evaluation) study design to compare the ability of biomarkers of systemic inflammation and biomarkers of gastrointestinal (GI) tissue damage to predict response to corticosteroid treatment, the incidence of clinically severe disease, 6-month nonrelapse mortality (NRM), and overall survival in patients with acute graft-versus-host disease (GVHD). We prospectively collected serum samples of newly diagnosed GVHD patients (n = 730) from 19 centers, divided them into training (n = 352) and validation (n = 378) cohorts, and measured TNFR1, TIM3, IL6, ST2, and REG3α via enzyme-linked immunosorbent assay. Performances of the 4 strongest algorithms from the training cohort (TNFR1 + TIM3, TNFR1 + ST2, TNFR1 + REG3α, and ST2 + REG3α) were evaluated in the validation cohort. The algorithm that included only biomarkers of systemic inflammation (TNFR1 + TIM3) had a significantly smaller area under the curve (AUC; 0.57) than the AUCs of algorithms that contained ≥1 GI damage biomarker (TNFR1 + ST2, 0.70; TNFR1 + REG3α, 0.73; ST2 + REG3α, 0.79; all P &lt; .001). All 4 algorithms were able to predict short-term outcomes such as response to systemic corticosteroids and severe GVHD, but the inclusion of a GI damage biomarker was needed to predict long-term outcomes such as 6-month NRM and survival. The algorithm that included 2 GI damage biomarkers was the most accurate of the 4 algorithms for all endpoints.
P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM
Al‐Kali, Aref , Borate, Uma , Cluzeau, Thomas , DeZern, A. E., Kobata, Kazuma, Lyons, Roger M. , Sallman, David A. , Xiao, Zhijian , Hoef, Marlies Van, Nourry-Boulot, Claire, Sadek, Islam Mohamad, IORDAN, Ana-Maria, Sabo, Jennifer L., Garcia‐Manero, G., Zeidan, Amer M. , Esteve, Jordi , Giagounidis, Aristoteles , Platzbecker, Uwe , Santini, Valeria , Sanz, Guillermo , Sekeres, Mikkael A. , Wei, Andrew H. , Ma, Fei

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 682-683

10.1097/01.hs9.0000846032.37876.c9 Get It